Icon Group, a global leader in integrated cancer care, has entered into a landmark agreement with Varian, a Siemens Healthineers company, to invest over USD $18.7 million in expanding access to next-generation cancer treatment technologies throughout the United Kingdom.
As part of the agreement, Icon will implement Varian’s state-of-the-art TrueBeam® linear accelerators and a suite of advanced imaging and software platforms—including RapidArc Dynamic (RAD), HyperSight™, and IDENTIFY®. This will mark the first time the full range of Varian’s hardware and software is deployed together in the UK, signifying a major step forward in delivering fast, precise, and patient-centred radiotherapy.
The rollout will begin at Icon Cancer Centre London, followed by new centres opening in Brighton, Warwickshire, and Derby, with additional sites to follow as Icon expands its footprint across the region.
A Major Commitment to Precision Cancer Care
“This significant investment allows us to continue setting the benchmark for precision-led cancer care,” said Aldo Rolfo, CEO of Icon Europe. “At Icon, we are dedicated to introducing the latest radiotherapy innovations and expanding access to world-class treatment in every community we serve.”
Technology Designed to Improve Outcomes and Experience
This new partnership brings some of Varian’s most advanced tools to UK patients:
TrueBeam® – A cutting-edge linear accelerator delivering high-speed, image-guided radiation therapy for various cancer types.
RapidArc Dynamic (RAD) – A next-gen planning and delivery platform that enhances treatment quality while reducing planning time by up to 70% and minimizing radiation exposure to healthy organs.
HyperSight™ – Advanced cone-beam CT imaging that offers sharper, faster anatomical images to support more precise treatment with reduced image acquisition times.
IDENTIFY® – A real-time surface-guided radiotherapy system that enhances targeting accuracy and may eliminate the need for permanent tattoos, improving patient comfort and dignity.
Transforming Radiotherapy in the UK
Dr Penny Kechagioglou, Icon Group’s UK Chief Medical Officer, emphasized the impact this technology will have on care delivery.
“This marks a major advancement in UK radiotherapy,” she said. “Currently, fewer than 30% of cancer patients in the UK receive radiotherapy—far below the global recommendation of 40–50%. With this technology, we can offer more timely, effective, and patient-friendly treatment to more people.”
A Shared Vision for the Future of Cancer Care
Virve Sarja, Head of Varian Europe, Middle East and Africa, expressed her enthusiasm for the partnership.
“We’re proud to deepen our collaboration with Icon to bring the most advanced radiotherapy solutions to patients across the UK,” she said. “Together, we’re not just enhancing technology—we’re reshaping what’s possible in cancer care by combining innovation with a human-centred approach.”